Newron Pharmaceuticals Builds a Presence in Switzerland with the Opening of a Clinical development Facility in Basle

Milan, Italy – August 30, 2007 - Newron Pharmaceuticals S.p.A. (“Newron”, SWX: NWRN), a research and development company focused on novel CNS and pain therapies, today announced that it is opening a clinical development facility in Basle, Switzerland, in September 2007. The new operations will be incorporated into a subsidiary fully owned by Newron, called Newron Suisse SA, and will complement Newron’s headquarter in Bresso, Milan. The Basle region is one of Europe’s key pharma/biotech clusters in which Newron will be well positioned to attract talented research and develop­ment professionals to further strengthen the Company’s international clinical development activities and to broaden its strong pipeline of compounds, targeting novel therapies for diseases of the Central Nervous System, and pain. Initially Newron Suisse will be staffed with five senior professionals, a gradual expansion is planned. Newron thanks the BaselArea Business Development for its support in the process.

Half-year results to be announced on 3 September 2007

Please note that Newron will now announce its half-year results on Monday 3 September 2007 rather than on the previously announced date of Friday 14 September 2007. The half-year report and press release will be available on Newron’s website from 7am CET.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System, particularly Parkinson´s disease (PD), and pain. Newron is undertaking phase III trials with safinamide for the treatment of PD in conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer´s disease, and other therapeutic applications. Safinamide is a unique molecule with a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent, reversible inhibition of MAO-B, and dopamine uptake) and reduction of glutamatergic activity by inhibiting glutamate release. Results of a six-month phase III trial of safinamide in PD as an add-on to dopamine agonist therapy demonstrated its benefit in motor symptoms and activities of daily living, as well as its improvement in cognitive function and good tolerability. Newron is conducting phase II trials with ralfinamide for the treatment of neuropathic and post dental extraction pain. A recently completed phase II placebo controlled study demonstrated the efficacy of ralfinamide in reducing neuropathic pain, as well as improving sleep and the ability to perform activities. The drug was well tolerated, with side effects comparable to placebo. Newron´s clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.

For more information, contact: Media Investors and analysts Italy Luca Benatti - CEO Phone: +39 02 6103 4 626 UK/Global media Julia Phillips Financial Dynamics Phone: +44 (0) 20 7269 7187

Switzerland Martin Meier-Pfister The Investor Relations Firm AG Phone: +41 43 244 81 40